Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy (Q24809183)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy	scientific article

Statements

instance of

scholarly article

0 references

review article

1 reference

stated in

PubMed

retrieved

19 November 2020

comment

1 reference

PubMed publication ID

15696203

title

Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy (English)

0 references

main subject

non-small-cell lung carcinoma

1 reference

stated in

PubMed

retrieved

19 November 2020

lung neoplasm

1 reference

stated in

PubMed

retrieved

19 November 2020

DNA mutational analysis

1 reference

stated in

PubMed

retrieved

19 November 2020

author name string

Akira Inoue

series ordinal

1

0 references

Toshihiro Nukiwa

series ordinal

2

0 references

language of work or name

English

0 references

publication date

January 2005

0 references

1 January 2005

3 references

stated in

PubMed Central

retrieved

3 April 2019

stated in

PubMed Central

retrieved

19 September 2019

stated in

PubMed Central

retrieved

19 November 2020

published in

PLOS MEDICINE

3 references

stated in

PubMed Central

retrieved

3 April 2019

stated in

PubMed Central

retrieved

19 September 2019

stated in

PubMed Central

retrieved

19 November 2020

volume

2

0 references

issue

1

0 references

page(s)

e13

0 references

copyright license

Creative Commons Attribution 4.0 International

3 references

stated in

Europe PubMed Central

retrieved

3 April 2019

stated in

Europe PubMed Central

retrieved

19 September 2019

stated in

Europe PubMed Central

retrieved

19 November 2020

copyright status

copyrighted

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

7 April 2017

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

7 April 2017

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

7 April 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

7 April 2017

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 September 2017

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 September 2017

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 September 2017

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 September 2017

Novel targets for lung cancer therapy: part II.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 September 2017

Severe acute interstitial pneumonia and gefitinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 November 2018

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545205

retrieved

28 November 2018

Identifiers

DOI

10.1371/JOURNAL.PMED.0020013

0 references

PMC publication ID

545205

0 references

PubMed publication ID

15696203

0 references

ResearchGate publication ID

8036872

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24809183&oldid=1648635932"